Capstone Asset Management Co. boosted its position in Celgene Corp. (NASDAQ:CELG) by 2.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 106,363 shares of the biopharmaceutical company’s stock after buying an additional 2,347 shares during the period. Capstone Asset Management Co.’s holdings in Celgene Corp. were worth $11,118,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Jolley Asset Management LLC increased its position in Celgene Corp. by 58.8% in the second quarter. Jolley Asset Management LLC now owns 1,215 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 450 shares in the last quarter. Smithfield Trust Co. increased its position in Celgene Corp. by 12.5% in the second quarter. Smithfield Trust Co. now owns 1,282 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 142 shares in the last quarter. Integrated Investment Consultants LLC increased its position in Celgene Corp. by 21.8% in the second quarter. Integrated Investment Consultants LLC now owns 1,339 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 240 shares in the last quarter. Feltz Wealth PLAN Inc. purchased a new position in Celgene Corp. during the second quarter worth approximately $148,000. Finally, Integrated Wealth Management increased its position in Celgene Corp. by 2.5% in the second quarter. Integrated Wealth Management now owns 1,664 shares of the biopharmaceutical company’s stock worth $164,000 after buying an additional 40 shares in the last quarter. 76.43% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Celgene Corp. (NASDAQ:CELG)

Celgene Corp. (NASDAQ:CELG) traded down 1.88% during midday trading on Wednesday, reaching $119.84. The company’s stock had a trading volume of 2,487,335 shares. Celgene Corp. has a 52 week low of $93.05 and a 52 week high of $127.00. The firm has a 50 day moving average price of $108.88 and a 200-day moving average price of $106.73. The firm has a market cap of $92.90 billion, a P/E ratio of 45.51 and a beta of 1.71.

Celgene Corp. (NASDAQ:CELG) last issued its earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.48 by $0.10. Celgene Corp. had a net margin of 19.71% and a return on equity of 70.48%. The business earned $2.98 billion during the quarter, compared to the consensus estimate of $2.84 billion. During the same period last year, the business posted $1.23 EPS. Celgene Corp.’s revenue was up 27.8% on a year-over-year basis. On average, analysts forecast that Celgene Corp. will post $5.92 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2016/11/30/celgene-corp-celg-shares-bought-by-capstone-asset-management-co.html.

Several brokerages recently issued reports on CELG. Canaccord Genuity set a $156.00 price target on Celgene Corp. and gave the stock a “buy” rating in a report on Sunday, September 18th. Vetr raised Celgene Corp. from a “hold” rating to a “buy” rating and set a $128.85 price target on the stock in a report on Tuesday. Oppenheimer Holdings Inc. began coverage on Celgene Corp. in a report on Tuesday. They issued an “outperform” rating and a $141.00 price target on the stock. Leerink Swann reissued a “market perform” rating and issued a $135.00 price target on shares of Celgene Corp. in a report on Monday, September 12th. Finally, Morgan Stanley reissued a “hold” rating and issued a $120.00 price target on shares of Celgene Corp. in a report on Wednesday, August 3rd. Four investment analysts have rated the stock with a hold rating and twenty-seven have given a buy rating to the stock. Celgene Corp. presently has an average rating of “Buy” and an average target price of $136.62.

In related news, Director Gilla Kaplan sold 9,710 shares of the firm’s stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $106.44, for a total value of $1,033,532.40. Following the completion of the sale, the director now directly owns 72,142 shares in the company, valued at approximately $7,678,794.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Richard W. Barker sold 20,000 shares of the firm’s stock in a transaction dated Friday, September 23rd. The shares were sold at an average price of $110.82, for a total transaction of $2,216,400.00. Following the completion of the sale, the director now owns 31,332 shares of the company’s stock, valued at $3,472,212.24. The disclosure for this sale can be found here. 0.97% of the stock is currently owned by corporate insiders.

About Celgene Corp.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Receive News & Stock Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related stocks with our FREE daily email newsletter.